Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ascendis Pharma A (ASND) Equity Income: 2019-2025

Historic Equity Income for Ascendis Pharma A (ASND) over the last 7 years, with Sep 2025 value amounting to -$8.8 million.

  • Ascendis Pharma A's Equity Income fell 82.84% to -$8.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.7 million, marking a year-over-year increase of 148.39%. This contributed to the annual value of -$21.7 million for FY2024, which is 9.70% down from last year.
  • Latest data reveals that Ascendis Pharma A reported Equity Income of -$8.8 million as of Q3 2025, which was down 89.09% from -$4.6 million recorded in Q2 2025.
  • Over the past 5 years, Ascendis Pharma A's Equity Income peaked at $36.0 million during Q4 2021, and registered a low of -$8.8 million during Q3 2025.
  • Its 3-year average for Equity Income is -$2.5 million, with a median of -$4.9 million in 2024.
  • In the last 5 years, Ascendis Pharma A's Equity Income skyrocketed by 2,127.09% in 2021 and then tumbled by 552.12% in 2023.
  • Quarterly analysis of 5 years shows Ascendis Pharma A's Equity Income stood at $36.0 million in 2021, then slumped by 122.56% to -$8.1 million in 2022, then soared by 61.27% to -$3.1 million in 2023, then slumped by 55.40% to -$4.9 million in 2024, then plummeted by 82.84% to -$8.8 million in 2025.
  • Its last three reported values are -$8.8 million in Q3 2025, -$4.6 million for Q2 2025, and $28.0 million during Q1 2025.